Slate Medicines agreed to combine with Fulcrum Therapeutics in a reverse merger, aiming to move toward a Nasdaq listing while financing migraine development. The deal follows Fulcrum’s earlier exit from its sickle cell program after regulatory concerns and a discontinuation tied to secondary cancer risk signals. Slate’s pipeline emphasis is on migraine therapeutics, including SLTE-1009, described as a PACAP inhibitor rather than a CGRP-targeting approach. The report said the combined entity will receive additional financing to support clinical work across multiple programs, with Phase 1 expected to begin for its lead candidate. The reverse merger also reframes capital efficiency for early-stage companies seeking public-market access without a traditional IPO. For the biotech sector, the transaction reinforces the ongoing pattern of non-traditional paths to funding and listing amid shifting market appetite for early oncology and neurology risk.